Open AccessThromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy
Author(s) -
Lisa B.E. Shields,
Michael W. Daniels,
Nataliya Mar,
Arash Rezazadeh Kalebasty
Publication year - 2021
Publication title -
world journal of clinical oncology
Language(s) - English
Resource type - Journals
ISSN - 2218-4333
DOI - 10.5306/wjco.v12.i3.183
Subject(s) - medicine , cisplatin , testicular cancer , chemotherapy , oncology , cancer
Testicular germ cell tumor (TGCT) is the most curable solid tumor and most common cancer among men 18-39 years. While cisplatin-based chemotherapy has significantly lengthened the survival of patients with TGCT, it is associated with a high rate of thromboembolic events (TEE).